Day One Biopharmaceuticals’ (DAWN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $50.00 price objective on the stock.

Several other equities research analysts have also recently weighed in on DAWN. Piper Sandler restated an overweight rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. JPMorgan Chase & Co. boosted their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an overweight rating in a research note on Monday. Needham & Company LLC boosted their target price on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a buy rating in a research note on Wednesday. The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a research note on Tuesday, February 27th. Finally, Oppenheimer restated a market perform rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Day One Biopharmaceuticals currently has an average rating of Moderate Buy and an average price target of $39.33.

Day One Biopharmaceuticals Trading Down 8.7 %

Shares of DAWN opened at $15.19 on Wednesday. The stock has a 50-day simple moving average of $15.28 and a 200-day simple moving average of $13.79. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, equities analysts predict that Day One Biopharmaceuticals will post -2.66 earnings per share for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Samuel C. Blackman sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total value of $322,200.00. Following the transaction, the insider now owns 1,224,662 shares of the company’s stock, valued at $19,729,304.82. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,781 shares of company stock worth $883,160. 8.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Arizona State Retirement System grew its holdings in Day One Biopharmaceuticals by 8.8% during the third quarter. Arizona State Retirement System now owns 12,363 shares of the company’s stock worth $152,000 after acquiring an additional 995 shares during the period. Quintet Private Bank Europe S.A. grew its holdings in Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Day One Biopharmaceuticals by 130.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock worth $27,000 after acquiring an additional 1,262 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in Day One Biopharmaceuticals by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after acquiring an additional 1,445 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in Day One Biopharmaceuticals by 9.7% during the third quarter. Principal Financial Group Inc. now owns 17,781 shares of the company’s stock worth $218,000 after acquiring an additional 1,569 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.